Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is viewed positively because Amtagvi is showing clear commercial traction, with 2Q26 revenue of $99.3 million up 66% year over year and full-year FY26 revenue guidance raised to $410 million to $420 million from $350 million to $370 million. The company’s expanding network of about 100 authorized treatment centers, more than 50 commercial patients per month, and an improved 56% gross margin from 41% in 1Q26 suggest stronger access, better operating leverage, and a more scalable manufacturing model. Its outlook is further supported by a $303.7 million cash balance, advancing NSCLC, sarcoma, and frontline melanoma programs, and approvals in Canada and Australia that reinforce the broader TIL platform.

Iovance Biotherapeutics is exposed to substantial clinical, regulatory, and commercial uncertainty because its value depends heavily on FDA and EMA approvals, and any failed or delayed trials could sharply impair its pipeline. Despite AMTAGVI, lifileucel, and other programs contributing to the model, the company still faces intense competition from checkpoint/Raf inhibitors and emerging CAR-T approaches in solid tumors, which could limit market adoption and pricing power. Fundamentally, heavy R&D spending and the possibility of needing additional capital create financing risk, while the bear case assumes lifileucel’s uptake weakens and commercial success falls to 10%, underscoring fragile execution.